About MannKind

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients.

In addition, MannKind is applying our novel technologies and services to support partner development efforts. More >

Worldwide rights to AFREZZA have been licensed to Sanofi. For more information about AFREZZA, please visit www.Afrezza.com.


Sanofi and MannKind Announce Afrezza®, the Only Inhaled Insulin, Now Available in the U.S. More >

News & Events

Nov 20, 2015 MannKind Announces Senior Management Changes More >
Nov 12, 2015 MannKind Announces Pricing of Registered Direct Offering More >
Nov 11, 2015 MannKind Confirms Planned Stock Sale More >